AR073701A1 - Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. - Google Patents
Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- AR073701A1 AR073701A1 ARP090103731A ARP090103731A AR073701A1 AR 073701 A1 AR073701 A1 AR 073701A1 AR P090103731 A ARP090103731 A AR P090103731A AR P090103731 A ARP090103731 A AR P090103731A AR 073701 A1 AR073701 A1 AR 073701A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr4ar5a
- cr4br5b
- alkyl
- haloalkyl
- independently
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
Abstract
Composiciones que comprenden estos compuestos, su uso para tratar condiciones de enfermedad neurodegenerativa mediante el uso de estos compuestos y de estas composiciones y métodos para identificar estos compuestos. Se proveen además, método para su preparacion. Reivindicacion 1: Un compuesto de formula (1), (2), (3), (4), (5), o (6) que comprende o una sal aceptable para uso farmacéutico o prodroga del mismo, caracterizado porque a es una union simple o doble; X es CHR6, C=CHR6, o NR6; X1 es CHR8 o NR8; U, V, W, e Y son cada uno independientemente -(CH2)p-; p en cada oportunidad es independientemente 0, 1 o 2; Z es -(CH2)q-; q es 1, 2, o 3; R1, R2, R3, y R4 son cada uno independientemente hidrogeno, alquilo, alquenilo, alquinilo, halogeno, ciano, -G1, -N(Rb)(R3a), -N(Ra)C(O)R1a, -N(Ra)C(O)O(R1a), -N(Ra)C(O)N(Rb)(R3a), -OR1a, -SR1a, -S(O)2R2a, o haloalquilo; donde Ra y Rb, en cada oportunidad, son cada uno independientemente hidrogeno, alquilo, o haloalquilo; R1a y R3a, en cada oportunidad, son cada uno independientemente hidrogeno, alquilo, haloalquilo, G1, o -(CR6aR7a)n-G1; R2a, en cada oportunidad, es independientemente alquilo, haloalquilo, G1, o -(CR6aR7a)n-G1; n, en cada oportunidad, es independientemente 1, 2, 3, 4, o 5; R6a y R7a, en cada oportunidad, son cada uno independientemente hidrogeno, halogeno, alquilo, o haloalquilo; G1 en cada oportunidad, es independientemente arilo, heteroarilo, heterociclo, o cicloalquilo, donde cada G1 no se sustituye o se sustituye independientemente con 1, 2, 3, 4, o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo, halogeno, ciano, oxo, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b, -C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)R3b), -(CR4bR5b)m-NO2, -(CR4bR5b)m-OR1b, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b), -(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), cianoalquilo, y haloalquilo; m, en cada oportunidad, es independientemente 1, 2, 3, 4, o 5; Ra y Rb, en cada oportunidad, son cada uno independientemente hidrogeno, alquilo, o haloalquilo; R1b y R3b, en cada oportunidad, son cada uno independientemente hidrogeno, alquilo, o haloalquilo; R2b, en cada oportunidad, es independientemente alquilo o haloalquilo; R4b y R5b, en cada oportunidad, son cada tino independientemente hidrogeno, halogeno, alquilo, o haloalquilo; R5 es hidrogeno, alquilo, G1, S(O)2R2a, S(O)2N(Rb)(R3a), -C(O)R1a, -C(O)OR1b, -C(O)N(Rb)(R3b), -(CR4aR5a)m-NO2, -(CR4aR5a)m-OR1a, -(CR4aR5a)m-OC(O)R1a, -(CR4aR5a)m-OC(O)N(Rb)(R3a), -(CR4aR5a)m-SR1a, -(CR4aR5a)m-S(O)2R2a, -(CR4aR5a)m-S(O)2N(Rb)(R3a), -(CR4aR5a)m-C(O)R1a, -(CR4aR5a)m-C(O)OR1a, -(CR4aR5a)m-C(O)N(Rb)(R3a), -(CR4aR5a)m-N(Rb)(R3a), -(CR4aR5a)m-N(Ra)C(O)R1a, -(CR4aR5a)m-N(Ra)C(O)O(R1a), -(CR4aR5a)m-N(Ra)C(O)N(Rb)(R3a), -(CR4aR5a)m-G1, cianoalquilo, o haloalquilo; R3a, en cada oportunidad, es independientemente hidrogeno, alquilo, haloalquilo, G1, o -(CR6aR7a)n-G1; R4a y R5a, en cada oportunidad, son cada uno independientemente hidrogeno, halogeno, alquilo, o haloalquilo; R6 es alquilo, S(O)2R2a, -C(O)R1a, -C(O)OR1a, C(O)N(Rb)(R3a), -(CR4aR5a)m-NO2, -(CR4aR5a)m-OR1a, -(CR4aR5a)m-OC(O)R1a, -(CR4aR5a)m-OC(O)N(Rb)(R3a), -(CR4aR5a)m-SR1a, -(CR4aR5a)m-S(O)2R2a, -(CR4aR5a)m-S(O)2N(Rb)(R3a), -(CR4aR5a)m-C(O)R1a, -(CR4aR5a)m-C(O)OR1a, -(CR4aR5a)m-C(O)N(Rb)(R3a), -(CR4aR5a)m-N(Rb)(R3a), -(CR4aR5a)m-N(Ra)C(O)R1a, -(CR4aR5a)m-N(Ra)C(O)O(R1a), -(CR4aR5a)m-N(Ra)C(O)N(Rb)(R3a), -(CR4aR5a)m-G1, -(CR4aR5a)m-G2-G1, -CR4a=CR5a-S(O)2R2a, -CR4a=R5a-S(O)2N(Rb)(R3a), -CR4a=CR5a-C(O)R1a, -CR4a=CR5a-C(O)OR1a, -CR4a=CR5a-G1, -G1, G2-G1, cianoalquilo, o haloalquilo; G2 es arilo, heteroarilo, heterociclo, o cicloalquilo no sustituido o sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo, halogeno, ciano, oxo, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b, -C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)R3b), -(CR4bR5b)m-NO2, -(CR4bR5b)m-OR1b, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b), -(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), cianoalquilo, y haloalquilo; R7 es hidrogeno, alquilo, -G1, -(CR4aR5a)m-NO2, -(CR4aR5a)m-OR1a, -(CR4aR5a)m-OC(O)R1a, -(CR4aR5a)m-OC(O)N(Rb)(R3a), -(CR4aR5a)m-SR1a, -(CR4aR5a)m-S(O)2R2a, -(CR4aR5a)m-S(O)2N(Rb)(R3a), -(CR4aR5a)m-C(O)R1a, -(CR4aR5a)m-C(O)OR1a, -(CR4aR5a)m-C(O)N(Rb)(R3a), -(CR4aR5a)m-N(Rb)(R3a), -(CR4aR5a)m-N(Ra)C(O)R1a, -(CR4aR5a)m-N(Ra)C(O)O(R1a), -(CR4aR5a)m-N(Ra)C(O)N(Rb)(R3a), -(CR4aR5a)m-G1, cianoalquilo, o haloalquilo; y R8 es -(CR4aR5a)m-G1, -(CR4aR5a)m-G2-G1, o -CR4a=CR5a-G1, con la condicion de que en un compuesto de formula (1), cuando R1, R2 y R4 son cada uno hidrogeno; R3 es hidrogeno o halogeno; U es CH2; V, W, e Y son cada uno -(CH2)p-, donde p es 0; Z es -(CH2)q-, donde q es 2 o 3; X es NR6; y R6 es alquilo, -G1, o -(CR4aR5a)m-G1, donde m es 1, R4a y R5a son hidrogeno y G1 es fenilo no sustituido o sustituido con alquilo, halogeno, hidroxi o -OR1a donde R1a es alquilo; R5 es diferente a hidrogeno, alquilo, -(CR4aR5a)m-G1, -C(O)R1a, -(CR4aR5a)m-OR1a, o -(CR4aR5a)m-C(O)R1a donde R1a es alquilo, arilo o heteroarilo, y G1 es arilo o heteroarilo; o con al condicion de que en un compuesto de formula (4), cuando a es una union doble; V es -(CH2)p-, donde p es 0; Y es -(CH2)p-, donde p es 2; Z es -(CH2)q-, donde q es 1; y X es NR6, entonces R6 es diferente a alquilo, C(O)R1a, -(CR4aR5a)mOR1a, -(CR4aR5a)mC(O)R1a, -(CR4aR5a)m-N(Rb)(R3a), -(CR4aR5a)m-G1, -CR4a=R5a-G1, -G1, cianoalquilo o haloalquilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10105408P | 2008-09-29 | 2008-09-29 | |
US22545209P | 2009-07-14 | 2009-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073701A1 true AR073701A1 (es) | 2010-11-24 |
Family
ID=42060424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103731A AR073701A1 (es) | 2008-09-29 | 2009-09-28 | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. |
Country Status (11)
Country | Link |
---|---|
US (2) | US9063126B2 (es) |
EP (1) | EP2344505A2 (es) |
JP (1) | JP2012504137A (es) |
CN (1) | CN102227431A (es) |
AR (1) | AR073701A1 (es) |
CA (1) | CA2737031A1 (es) |
MX (1) | MX2011003435A (es) |
PA (1) | PA8843701A1 (es) |
TW (1) | TW201018694A (es) |
UY (1) | UY32147A (es) |
WO (1) | WO2010036998A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
US9625475B2 (en) * | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
US8569287B2 (en) | 2008-10-31 | 2013-10-29 | Medivation Technologies, Inc. | Azepino[4,5-B]indoles and methods of use |
EP2424364A4 (en) | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
AU2010298166B2 (en) | 2009-09-23 | 2015-09-17 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
AU2010298168B2 (en) * | 2009-09-23 | 2015-11-19 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
BR112012006648A2 (pt) | 2009-09-23 | 2019-09-24 | Medivation Neurology Inc | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit |
US8778959B2 (en) | 2009-12-17 | 2014-07-15 | Abbvie Inc. | AZA-bridged ring-fused indoles and indolines |
WO2011075487A1 (en) * | 2009-12-17 | 2011-06-23 | Abbott Laboratories | Bridgehead amine ring -fused indoles and indolines useful to treat neurodegenerative and neuropsychiatry disorders |
WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
US9187471B2 (en) * | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
IN2013MN01699A (es) | 2011-02-18 | 2015-06-12 | Medivation Technologies Inc | |
US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
US20140303144A1 (en) | 2011-02-18 | 2014-10-09 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
US8921576B2 (en) | 2011-10-19 | 2014-12-30 | Kowa Company, Ltd. | Spiroindoline compound, and medicinal agent comprising same |
WO2013085849A2 (en) * | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Sulfate esters of noribogaine |
JP2015500833A (ja) * | 2011-12-09 | 2015-01-08 | デメレックス, インコーポレイテッド | ノルイボガインのリン酸エステル |
WO2013177241A1 (en) | 2012-05-22 | 2013-11-28 | Trustees Of Dartmouth College | Method for synthesizing cycloalkanyl(b}indoles, cycloalkanyl(b) benzofurans, cycloalkanyl(b)benzothiophenes, compounds and methods of use |
EP2934541A4 (en) | 2012-12-20 | 2016-08-03 | Demerx Inc | NORIBOGAINE SUBSTITUTE |
CN114409680B (zh) * | 2018-01-19 | 2023-11-21 | 上海怡立舍生物技术有限公司 | Ppar激动剂及其应用 |
CN113121543B (zh) * | 2021-04-26 | 2022-03-15 | 重庆理工大学 | 一种吖庚环并[4,5-b]吲哚化合物的制备方法 |
CN116589726B (zh) * | 2023-07-11 | 2023-09-22 | 中北大学 | 一种检测酪氨酸的复合膜传感器的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3409628A (en) * | 1966-05-12 | 1968-11-05 | Hoffmann La Roche | 5-(3-pyridylethyl)pyridoindole derivatives |
DE2854941A1 (de) | 1978-12-20 | 1980-07-10 | Troponwerke Gmbh & Co Kg | Indolo eckige klammer auf 3.2-b eckige klammer zu chinuclidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4591983A (en) | 1984-07-09 | 1986-05-27 | Teknowledge, Inc. | Hierarchical knowledge system |
KR100195399B1 (ko) | 1987-05-04 | 1999-06-15 | 보니데이비스 | 알쯔하이머 병 치료용 의약 |
US5250537A (en) * | 1992-03-13 | 1993-10-05 | Scios Nova Inc. | 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole,-6,7,8,9,10-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives |
US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
DE19615265A1 (de) | 1996-04-18 | 1997-12-04 | Bayer Ag | Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole |
US5811551A (en) * | 1996-08-13 | 1998-09-22 | Merck & Co., Inc. | Palladium catalyzed indolization |
ES2223536T3 (es) * | 1999-06-15 | 2005-03-01 | Bristol-Myers Squibb Pharma Company | Gamma-carbolinas condensadas con heterociclos sustituidas. |
EP1219607B1 (en) | 1999-09-02 | 2011-04-06 | Shionogi & Co., Ltd. | Integrase inhibitors containing aromatic heterocycle derivatives |
CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
AR034264A1 (es) | 2000-09-20 | 2004-02-18 | Upjohn Co | Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas |
DE60219788T2 (de) | 2001-06-05 | 2008-01-17 | Lilly Icos Llc, Wilmington | Tetrazyklische verbindungen als pde5-inhibitoren |
ES2250689T3 (es) | 2001-08-08 | 2006-04-16 | PHARMACIA & UPJOHN COMPANY LLC | 1h-pirido(4,3-b)indoles terapeuticos. |
WO2004063156A1 (en) | 2003-01-08 | 2004-07-29 | Biovitrum Ab | Novel indole derivates as fabp-4 inhibitors |
US20050143371A1 (en) * | 2003-07-23 | 2005-06-30 | Pharmacia Corporation | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors |
US7309699B2 (en) * | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
RS50796B (sr) | 2004-03-09 | 2010-08-31 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterociklil-1,2,3-triazol-1-il]-n-aril-benzamidi kao inhibitori produkcije citokina za lečenje hroničnih inflamatornih oboljenja |
US7592454B2 (en) * | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
AU2006275694A1 (en) * | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists |
EP1747779A1 (en) | 2005-07-28 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
WO2008067863A2 (en) | 2006-10-24 | 2008-06-12 | Congenia S.R.L. | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt |
US20100152108A1 (en) | 2006-10-27 | 2010-06-17 | Medivation Neurology, Inc. | Methods and combination therapies for treating alzheimer's disease |
RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
FR2911142A1 (fr) * | 2007-01-05 | 2008-07-11 | Servier Lab | Nouveaux derives aminopyrrolo[1,2-a]indole et aminopyridazino[1,6-a]indole,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
TW200848417A (en) * | 2007-02-22 | 2008-12-16 | Organon Nv | Indole derivatives |
AU2008221667A1 (en) * | 2007-03-06 | 2008-09-12 | Astrazeneca Ab | Novel 2-heteroaryl substituted indoles 695 |
EP3663294A1 (en) | 2007-03-12 | 2020-06-10 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
WO2009001129A1 (en) | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
CA2700160A1 (en) | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
JP5679538B2 (ja) | 2008-03-24 | 2015-03-04 | メディベイション テクノロジーズ, インコーポレイテッド | ピリド[3,4−b]インドールおよびその使用 |
BR112012006648A2 (pt) * | 2009-09-23 | 2019-09-24 | Medivation Neurology Inc | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit |
WO2011075487A1 (en) | 2009-12-17 | 2011-06-23 | Abbott Laboratories | Bridgehead amine ring -fused indoles and indolines useful to treat neurodegenerative and neuropsychiatry disorders |
-
2009
- 2009-09-28 CA CA2737031A patent/CA2737031A1/en not_active Abandoned
- 2009-09-28 EP EP09793046A patent/EP2344505A2/en not_active Withdrawn
- 2009-09-28 UY UY0001032147A patent/UY32147A/es not_active Application Discontinuation
- 2009-09-28 WO PCT/US2009/058553 patent/WO2010036998A2/en active Application Filing
- 2009-09-28 US US12/568,085 patent/US9063126B2/en not_active Expired - Fee Related
- 2009-09-28 TW TW098132802A patent/TW201018694A/zh unknown
- 2009-09-28 PA PA20098843701A patent/PA8843701A1/es unknown
- 2009-09-28 CN CN2009801478287A patent/CN102227431A/zh active Pending
- 2009-09-28 AR ARP090103731A patent/AR073701A1/es unknown
- 2009-09-28 JP JP2011529302A patent/JP2012504137A/ja not_active Withdrawn
- 2009-09-28 MX MX2011003435A patent/MX2011003435A/es not_active Application Discontinuation
-
2015
- 2015-05-18 US US14/715,330 patent/US20150353550A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2737031A1 (en) | 2010-04-01 |
US9063126B2 (en) | 2015-06-23 |
WO2010036998A2 (en) | 2010-04-01 |
CN102227431A (zh) | 2011-10-26 |
MX2011003435A (es) | 2011-05-02 |
EP2344505A2 (en) | 2011-07-20 |
US20150353550A1 (en) | 2015-12-10 |
WO2010036998A3 (en) | 2011-03-03 |
PA8843701A1 (es) | 2010-05-26 |
JP2012504137A (ja) | 2012-02-16 |
UY32147A (es) | 2010-04-30 |
US20100087471A1 (en) | 2010-04-08 |
TW201018694A (en) | 2010-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
AR054799A1 (es) | Derivados de oxindol | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
AR102389A1 (es) | Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit | |
TR201906416T4 (tr) | Hiv inhibitörü bileşiklerin fosfonat analogları. | |
AR082154A1 (es) | DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4 | |
CO6140024A2 (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer | |
CO6660514A2 (es) | Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih | |
PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
PA8828201A1 (es) | Compuestos triazina como inhibidores mtor y quinasa p13 | |
PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
PE20141032A1 (es) | Inhibidores del virus de la hepatitis c | |
CO6592102A2 (es) | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
AR049647A1 (es) | Cis-imidazolinas | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
AR036778A1 (es) | Compuesto derivado de oxazolidinona sustituida y/o isoxazolina sustituida, profarmacos, su uso en la fabricacion de medicamentos, composicion farmaceutica y proceso para prepararlos | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
AR042833A1 (es) | Derivados de pirrolopiridazina y procedimiento para su preparacion | |
ECSP15035530A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |